Latest News & Stories
Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
Sabin has sent more than 640 doses of its investigational cAd3-Marburg Vaccine to Ethiopia to support the country’s response to its first-ever outbreak of Marburg virus disease.
Six in One: How Sabin is Supporting Hexavalent Vaccine Adoption
The hexavalent vaccine protects against six diseases in a one shot — improving efficiency, cutting costs, and saving lives. Sabin and partners are generating timely evidence and fostering collaboration to support smooth adoption.
Global Immunization Insights Dashboard
Sabin's dashboard provides a broader view of the factors impacting immunization in order to better understand what is needed to reach 1 billion children with vaccines by the end of the decade.
Local Impact, Global Change
Explore how Sabin’s partners drive impact on the ground. Discover their stories here, and check back for updates on new locations and projects.
Confronting Deadly Diseases
Vaccines are our best defense against disease. Yet, we still have lethal diseases that need a vaccine solution urgently. Sabin’s R&D team is tackling two such threats: Sudan ebolavirus and Marburg virus disease. There are no approved vaccines for either of these viruses which have left behind a trail of outbreaks, ending many lives and livelihoods in Africa. Sabin’s vaccines are in Phase 2 clinical trials in Uganda and Kenya.
Making a Case for Vaccines
We make vaccines more accessible, enable innovation and expand immunization across the globe.